SGX To Focus On BCR-ABL Partnership After Discontinuing Troxatyl Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II/III trial in AML patients halted due to low response rates, but SGX says it will focus on a collaboration with Novartis.
You may also be interested in...
SGX Pharmaceuticals Reports Toxicity With Lead Oncology Candidate In Phase I
CEO Grey acknowledges setback but points to second MET inhibitor and Novartis-partnered BCR-ABL inhibitor program as promising.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.